other material
confidence high
sentiment positive
materiality 0.75
Editas Medicine prices $125M public offering of shares and warrants
Editas Medicine, Inc.
- Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.
- Warrants exercisable at $3.50/share, expire upon EDIT-401 Phase 1 data milestone or within 3 years.
- If all warrants exercised, additional proceeds ~$194.4M; net proceeds estimated ~$117M.
- Cash runway extended into second half of 2028 based on current plans.
- Underwriters: Cantor Fitzgerald and Wells Fargo; closing expected May 27, 2026.